Therapy for Duchenne muscular dystrophy: renewed optimism from genetic approaches (Q44671291)

5 December 2017

title

Therapy for Duchenne muscular dystrophy: renewed optimism from genetic approaches (English)

1 reference

Duchenne muscular dystrophy

5 December 2017

main subject

1 reference

3

Kay E Davies

1 reference

5 December 2017

1

Rebecca J Fairclough

1 reference

5 December 2017

Matthew J Wood

2

1 reference

5 December 2017

publication date

23 April 2013

1 reference

5 December 2017

published in

Nature Reviews Genetics

1 reference

5 December 2017

volume

14

1 reference

5 December 2017

issue

6

1 reference

5 December 2017

page(s)

373-378

1 reference

Theoretic applicability of antisense-mediated exon skipping for Duchenne muscular dystrophy mutations

5 December 2017

cites work

1 reference

Pharmacologically targeting the primary defect and downstream pathology in Duchenne muscular dystrophy

21 January 2018

1 reference

Gene therapy for severe combined immunodeficiency: are we there yet?

21 January 2018

1 reference

Novel adeno-associated viral vectors for retinal gene therapy

21 January 2018

1 reference

Factor IX expression in skeletal muscle of a severe hemophilia B patient 10 years after AAV-mediated gene transfer

21 January 2018

1 reference

Current status of pharmaceutical and genetic therapeutic approaches to treat DMD.

21 January 2018

1 reference

Dystrophins carrying spectrin-like repeats 16 and 17 anchor nNOS to the sarcolemma and enhance exercise performance in a mouse model of muscular dystrophy.

21 January 2018

1 reference

Gene therapy for muscular dystrophy: lessons learned and path forward

21 January 2018

1 reference

Sustained alpha-sarcoglycan gene expression after gene transfer in limb-girdle muscular dystrophy, type 2D.

21 January 2018

1 reference

Dystrophin immunity in Duchenne's muscular dystrophy.

21 January 2018

1 reference

Successful regional delivery and long-term expression of a dystrophin gene in canine muscular dystrophy: a preclinical model for human therapies

21 January 2018

1 reference

Sense from nonsense: therapies for premature stop codon diseases.

21 January 2018

1 reference

PTC124 targets genetic disorders caused by nonsense mutations

21 January 2018

1 reference

Read-through strategies for suppression of nonsense mutations in Duchenne/ Becker muscular dystrophy: aminoglycosides and ataluren (PTC124).

21 January 2018

1 reference

The 6-minute walk test as a new outcome measure in Duchenne muscular dystrophy.

21 January 2018

1 reference

Read-through compound 13 restores dystrophin expression and improves muscle function in the mdx mouse model for Duchenne muscular dystrophy

21 January 2018

1 reference

Cancer syndromes and therapy by stop-codon readthrough

21 January 2018

1 reference

Targeting RNA to treat neuromuscular disease

21 January 2018

1 reference

Local restoration of dystrophin expression with the morpholino oligomer AVI-4658 in Duchenne muscular dystrophy: a single-blind, placebo-controlled, dose-escalation, proof-of-concept study

21 January 2018

1 reference

Exon skipping and dystrophin restoration in patients with Duchenne muscular dystrophy after systemic phosphorodiamidate morpholino oligomer treatment: an open-label, phase 2, dose-escalation study

21 January 2018

1 reference

Systemic administration of PRO051 in Duchenne's muscular dystrophy

21 January 2018

1 reference

Optimizing tissue-specific antisense oligonucleotide-peptide conjugates

21 January 2018

1 reference

Rational design of antisense oligomers to induce dystrophin exon skipping.

21 January 2018

1 reference

Bodywide skipping of exons 45-55 in dystrophic mdx52 mice by systemic antisense delivery

21 January 2018

1 reference

miRNAs as serum biomarkers for Duchenne muscular dystrophy

21 January 2018

1 reference

Expression analysis in multiple muscle groups and serum reveals complexity in the microRNA transcriptome of the mdx mouse with implications for therapy

21 January 2018

1 reference

Serum matrix metalloproteinase-9 (MMP-9) as a biomarker for monitoring disease progression in Duchenne muscular dystrophy (DMD).

21 January 2018

1 reference

Antitumorigenic potential of STAT3 alternative splicing modulation

21 January 2018

1 reference

Pharmacological strategies for muscular dystrophy

21 January 2018

1 reference

Utrophin upregulation for treating Duchenne or Becker muscular dystrophy: how close are we?

21 January 2018

1 reference

Sarcolemmal nNOS anchoring reveals a qualitative difference between dystrophin and utrophin.

21 January 2018

1 reference

Non-toxic ubiquitous over-expression of utrophin in the mdx mouse

21 January 2018

1 reference

Functional substitution by TAT-utrophin in dystrophin-deficient mice

21 January 2018

1 reference

Modulation of utrophin A mRNA stability in fast versus slow muscles via an AU-rich element and calcineurin signaling.

21 January 2018

1 reference

A cell-based high-throughput screening assay for posttranscriptional utrophin upregulation

21 January 2018

1 reference

Daily treatment with SMTC1100, a novel small molecule utrophin upregulator, dramatically reduces the dystrophic symptoms in the mdx mouse

21 January 2018

1 reference

Biglycan recruits utrophin to the sarcolemma and counters dystrophic pathology in mdx mice

21 January 2018

1 reference

Calcineurin-NFAT signaling, together with GABP and peroxisome PGC-1{alpha}, drives utrophin gene expression at the neuromuscular junction.

21 January 2018

1 reference

PGC-1alpha regulates the neuromuscular junction program and ameliorates Duchenne muscular dystrophy.

21 January 2018

1 reference

Expression of full-length utrophin prevents muscular dystrophy in mdx mice

21 January 2018

1 reference

Medicinal chemistry of fetal hemoglobin inducers for treatment of beta-thalassemia

21 January 2018

1 reference

Safety, tolerability, and pharmacokinetics of PTC124, a nonaminoglycoside nonsense mutation suppressor, following single- and multiple-dose administration to healthy male and female adult volunteers

21 January 2018

1 reference

In vivo comparison of 2'-O-methyl phosphorothioate and morpholino antisense oligonucleotides for Duchenne muscular dystrophy exon skipping

21 January 2018

1 reference

Dystrophin levels as low as 30% are sufficient to avoid muscular dystrophy in the human

21 January 2018

1 reference

Molecular basis of muscular dystrophies.

21 January 2018

1 reference

Local dystrophin restoration with antisense oligonucleotide PRO051

31 March 2020

1 reference

Naturally occurring utrophin correlates with disease severity in Duchenne muscular dystrophy

31 March 2020

1 reference

Low dystrophin levels increase survival and improve muscle pathology and function in dystrophin/utrophin double-knockout mice

31 March 2020

1 reference

Nitric oxide signalling pathway in Duchenne muscular dystrophy mice: up-regulation of L-arginine transporters

31 March 2020

1 reference

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1038/NRG3460

1 reference

5 December 2017

1 reference